<DOC>
	<DOCNO>NCT00280956</DOCNO>
	<brief_summary>The primary objective study evaluate long-term tolerability safety natalizumab administer dose 300 mg intravenously ( IV ) subject Crohn 's Disease previously participate study CD251 , CD301 , CD303 , CD306 , CD307 .</brief_summary>
	<brief_title>Open Label Natalizumab Safety Extension Study Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Male Female Subjects 18 year old Crohn 's Disease participate study CD251 , CD301 , CD303 , CD306 , CD307 per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>